epcoritamab
genmab,abbvie
['epcore,nhl,2', 'epcore,nhl,1', 'epcore,nhl,i,(-ii)', 'lymsm', 'nhl', 'epcore,nhl,3']
epcore nhl-1 lbcl #17icml:
- 157 pts (61% primary refractory, 39% prior car), mfu 20 mo
- orr 63% (cr 39%), mdor 16 mo, mdocr 21 mo
- 15 gr5 aes (half covid), 3% gr3 crs, 11% d/c d/t aes
impressive, especially for pts who achieve cr &amp; post-car (altho indefinite treatment). #lymsm 
Lymphoma doc & patient-reported outcomes researcher in #lymsm and #mmsm @CUHematology. Founder of https://t.co/kN6qeGFEox, @inTrainingDoc & @inHouseMag. 🏳️‍🌈